Friday, September 22, 2023
Clinical Advances in
Chronic rhinosinusitis (CRS) is a major cause of morbidity, lost productivity, and health expenditures in the United States. Though inflammatory in nature, the etiology of CRS is multifactorial and not attributable to any single factor. Surgery and intranasal steroids are the mainstays of therapy. Recent studies suggest that endotyping of CRS patients may soon allow for the use of biologic agents that target specific inflammatory pathways. This page provides education on evidence-based treatments for CRS, including devices that may improve delivery of therapies to the sinuses.
Supported by an independent educational grant from
OptiNose US, Inc.
This resource provides a concise overview of treatment options for CRS.
Download
Chair
Vice Chairman and Section Head
Head and Neck Institute, Cleveland Clinic
Cleveland, Ohio
Professor, Chief-Rhinology & Skull Base Surgery
Vanderbilt University Medical Center
Nashville, Tennessee
Professor
Russell E. Bridwell, MD, Endowed Chair
University of Kansas Medical Center
Kansas City, Kansas
Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts
Professor
Director, Division of Rhinology
Department of Otorhinolaryngology
Head and Neck Surgery
University of Pennsylvania
Philadelphia, Pennsylvania
Professor of Medicine
Director of Clinical Research
Northwestern University
Feinberg School of Medicine
Chicago, Illinois
Chair
Has disclosed the following relevant financial relationships
Served as an advisor or consultant for: Olympus Therapeutics; Acclarent
Has disclosed the following relevant financial relationships
Served as an advisor or consultant for: Olympus Therapeutics; Intersect ENT
Has disclosed the following relevant financial relationships
Served as an advisor or consultant for: Olympus Therapeutics; Medtronic, Inc.; Acclarent
Has disclosed the following relevant financial relationships
Served as an advisor or consultant for: Genentech, Inc.; OptiNose; Regeneron Pharmaceuticals, Inc.; Sanofi
Has disclosed no relevant financial relationships
Has disclosed the following relevant financial relationships
Served as an advisor or consultant for: OptiNose; Regeneron Pharmaceuticals, Inc.; Sanofi
Received grants for clinical research from: AstraZeneca Pharmaceuticals LP; Regeneron Pharmaceuticals, Inc.; Sanofi